Remicade and Hepatosplenic t-cell lymphoma - from FDA reports


Summary

Hepatosplenic t-cell lymphoma is found among people who take Remicade, especially for people who are male, 20-29 old , have been taking the drug for 2 - 5 years, also take medication Mercaptopurine, and have Inflammatory bowel disease. This review analyzes which people have Hepatosplenic t-cell lymphoma with Remicade. It is created by eHealthMe based on reports of 126,627 people who have side effects when taking Remicade from FDA , and is updated regularly.

What to expect?

If you take Remicade and have Hepatosplenic t-cell lymphoma, find out what symptoms you could have in 1 year or longer.

You are not alone!

Join a support group for people who take Remicade and have Hepatosplenic t-cell lymphoma

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA since 1977. Our tools are simple to use, anonymous and free. Start now >>>

On Sep, 25, 2017

126,627 people reported to have side effects when taking Remicade.
Among them, 300 people (0.24%) have Hepatosplenic t-cell lymphoma


Number of reports submitted per year:

Could Remicade cause Hepatosplenic t-cell lymphoma?

Time on Remicade when people have Hepatosplenic t-cell lymphoma *:

  • < 1 month: 19.7 %
  • 1 - 6 months: 28.79 %
  • 6 - 12 months: 4.55 %
  • 1 - 2 years: 1.52 %
  • 2 - 5 years: 43.94 %
  • 5 - 10 years: 1.52 %
  • 10+ years: 0.0 %

Gender of people who have Hepatosplenic t-cell lymphoma when taking Remicade *:

  • female: 14.79 %
  • male: 85.21 %

Age of people who have Hepatosplenic t-cell lymphoma when taking Remicade *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 24.89 %
  • 20-29: 33.94 %
  • 30-39: 25.79 %
  • 40-49: 1.36 %
  • 50-59: 9.05 %
  • 60+: 4.98 %

Top conditions involved for these people *:

  • Inflammatory Bowel Disease (15 people, 5.00%)
  • Diarrhea (11 people, 3.67%)
  • Juvenile Rheumatoid Arthritis (10 people, 3.33%)
  • Irritable Bowel Syndrome (10 people, 3.33%)
  • Colitis (10 people, 3.33%)

Top co-used drugs for these people *:

  • Mercaptopurine (105 people, 35.00%)
  • Azathioprine (93 people, 31.00%)
  • Imuran (60 people, 20.00%)
  • Asacol (56 people, 18.67%)
  • Humira (46 people, 15.33%)

Top other side effects for these people *:

  • Thrombocytopenia (38 people, 12.67%)
  • Drug Ineffective (32 people, 10.67%)
  • Sepsis (31 people, 10.33%)
  • Leukopenia (31 people, 10.33%)
  • Fever (28 people, 9.33%)

* Approximation only. Some reports may have incomplete information.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Subscribe to the study: get notified of updates to the study.

Do you have Hepatosplenic t-cell lymphoma when taking Remicade?

Expand the study to include all drugs with the same ingredients

Hepatosplenic t-cell lymphoma and drugs with ingredients of infliximab.

Expand the study to include reports from both FDA and eHealthMe

Hepatosplenic t-cell lymphoma and Remicade from FDA and eHealthMe reports

Remicade

Remicade has active ingredients of infliximab. It is often used in crohn's disease. (latest outcomes from Remicade 127,731 users)

Hepatosplenic t-cell lymphoma

Hepatosplenic t-cell lymphoma (neoplasm comprising medium-sized cytotoxic t-cells that show a significant sinusoidal infiltration in the liver, spleen, and bone marrow) has been reported by people with crohn's disease, ulcerative colitis, inflammatory bowel disease, juvenile rheumatoid arthritis, rheumatoid arthritis (latest reports from 491 Hepatosplenic t-cell lymphoma patients).

Browse all side effects of Remicade

a b c d e f g h i j k l m n o p q r s t u v w x y z

Drugs that are associated with Hepatosplenic t-cell lymphoma

Hepatosplenic t-cell lymphoma

Could your condition cause Hepatosplenic t-cell lymphoma

Hepatosplenic t-cell lymphoma

Related studies

What would happen?

Forecast new side effects and undetected conditions when you take Remicade and have Hepatosplenic t-cell lymphoma.

Questions to the study

More questions >

User reviews to the study

More reviews >